Use of nonpeptide bradykinin antagonists for the treatment and prevention of chronic fibrogenetic liver disorders, acute liver disorders and the complications associated therewith
CA 2205780 A1 · Owner: Hoechst Aktiengesellschaft · Inventors: Hropot, Max; Bickel, Martin; Heitsch, Holger
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of nonpeptide bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders (hepatic cirrhosis and hepatic fibrosis) acute liver disorders, and for the prevention of complications in particular for the prophylaxis or, treatment of portal hypertension decompensation symptoms such as, ascites edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension collateral circulationand hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 22, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 22, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 22, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.